CVS HEALTH CORP will remove JOHNSON & JOHNSON's psoriasis drug Stelara from its primary drug lists starting July 1. The pharmacy benefit unit will pivot to lower-cost biosimilars to reduce expenses for its health plan clients. This shift pressures high-margin biologics as cheaper alternatives gain traction in the specialty drug market.

CVS Caremark Pivots to Stelara Biosimilars